• Delfi Diagnostics announced new clinical utility data from its L301 FIRSTLUNG cluster-randomized trial will be presented in a late-breaking oral session at American Thoracic Society 2026 meeting in Orlando, running May 15-20.
• Study evaluated whether access to blood-based lung cancer testing in primary care changes real-world screening behavior versus reliance on low-dose CT alone.
• Company framed results as clear evidence that offering blood testing can lift overall lung cancer screening uptake, positioning FirstLook Lung as a practical entry point that fits routine lab workflows.
• Additional ATS presentations will also cover early implementation experience across health systems, including feasibility of at-home blood collection aimed at improving reach in under-resourced communities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delfi Diagnostics Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.